Substance / Medication

Glycine

Overview

Active Ingredient
glycine
RxNorm CUI
4919

Indications

Aminosyn II, Sulfite-Free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN II SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn II can be administered

Labeler: ICU Medical Inc.Updated: 2025-11-02T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Pharmacy Bulk Package – Not For Direct Infusion.

Contraindications

When this intervention should not be used

This preparation should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Progressive Encephalomyelitis With Rigidity and Myoclonus With Glycine Receptor Antibodies: Clinical Features and Outcomes.
Guasp Mar, Saiz Albert, Ruiz-Vives Marina et al. · Neurol Neuroimmunol Neuroinflamm · 2025
PMID: 40953327Meta-AnalysisFull text (PMC)
The effect of glycine administration on the characteristics of physiological systems in human adults: A systematic review.
Soh Janjira, Raventhiran Shivaanishaa, Lee Jasinda H et al. · Geroscience · 2024
PMID: 37851316Meta-AnalysisFull text (PMC)
Emerging role of osmoprotectant glycine betaine to mitigate heavy metals toxicity in plants: a systematic review.
Sharma Jyoti, Kumar Sandeep, Singh Pooja et al. · Biol Futur · 2024
PMID: 38183566Meta-Analysis
Effect of Dimethyloxalylglycine on Stem Cells Osteogenic Differentiation and Bone Tissue Regeneration-A Systematic Review.
Dong Qiannan, Fei Xiuzhi, Zhang Hengwei et al. · Int J Mol Sci · 2024
PMID: 38612687Meta-AnalysisFull text (PMC)
Glycine transporters in schizophrenia. A new hope or informational noise?
Zakowicz Przemysław, Pawlak Joanna · Psychiatr Pol · 2022
PMID: 35988070Meta-Analysis
Genetic Determinants of Circulating Glycine Levels and Risk of Coronary Artery Disease.
Jia Qiong, Han Yi, Huang Pin et al. · J Am Heart Assoc · 2019
PMID: 31070104Meta-AnalysisFull text (PMC)
Assessing the causal association of glycine with risk of cardio-metabolic diseases.
Wittemans Laura B L, Lotta Luca A, Oliver-Williams Clare et al. · Nat Commun · 2019
PMID: 30837465Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Glycine (substance)
SNOMED CT
15331006
UMLS CUI
C0017890
RxNorm CUI
4919
Labeler
ICU Medical Inc.

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

1
Conditions
1
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.